NASDAQ:FNCH Finch Therapeutics Group (FNCH) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free FNCH Stock Alerts $2.30 -0.49 (-17.56%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$2.25▼$2.6350-Day Range$2.08▼$3.4252-Week Range$1.86▼$16.74Volume117,052 shsAverage Volume38,041 shsMarket Capitalization$3.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Finch Therapeutics Group alerts: Email Address Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Finch Therapeutics Group Stock (NASDAQ:FNCH)Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.Read More FNCH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FNCH Stock News HeadlinesMarch 31, 2024 | insidertrades.comJeffery A. Smisek Sells 6,642 Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) StockApril 20, 2024 | americanbankingnews.comFinch Therapeutics Group (NASDAQ:FNCH) Shares Down 5.1% April 25, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 14, 2024 | fool.comFinch Therapeutics Group (NASDAQ: FNCH)March 25, 2024 | investorplace.comFNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023March 7, 2024 | investing.comFinch Therapeutics Group Inc (FNCH)February 22, 2024 | benzinga.comFinch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest ReportNovember 5, 2023 | morningstar.comFinch Therapeutics Group Inc FNCHApril 25, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…August 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)June 9, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common StockMay 13, 2023 | msn.comHC Wainwright & Co. Reiterates Finch Therapeutics Group (FNCH) Buy RecommendationMay 12, 2023 | marketwatch.com8-K: Finch Therapeutics Group, Inc.May 10, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 10, 2023 | finance.yahoo.comFinch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesApril 25, 2023 | finance.yahoo.comFinch Therapeutics Announces Executive Leadership TransitionsApril 22, 2023 | finanznachrichten.deFINCH THERAPEUTICS GROUP INCApril 18, 2023 | finance.yahoo.comFinch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License AgreementApril 4, 2023 | markets.businessinsider.comFinch Therapeutics Group (FNCH) Gets a Buy from H.C. WainwrightApril 3, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 25, 2023 | msn.comLooking Into Finch Therapeutics Group's Return On Capital EmployedMarch 25, 2023 | finance.yahoo.comFinch Therapeutics Group Full Year 2022 Earnings: Misses ExpectationsMarch 23, 2023 | finance.yahoo.comFinch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesJanuary 24, 2023 | finance.yahoo.comMicrobiome startup cuts 95% of remaining staff in 3rd layoff in 9 monthsJanuary 24, 2023 | marketwatch.comFinch Therapeutics Ending Phase 3 Study, Cutting Most of Workforce >FNCHJanuary 24, 2023 | finance.yahoo.comFinch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other AssetsNovember 11, 2022 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)See More Headlines Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today4/24/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FNCH CUSIPN/A CIK1733257 Webwww.finchtherapeutics.com Phone617-229-6499FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($47.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,750,000.00 Net MarginsN/A Pretax Margin-73,098.12% Return on Equity-136.63% Return on Assets-57.40% Debt Debt-to-Equity RatioN/A Current Ratio6.33 Quick Ratio6.33 Sales & Book Value Annual Sales$110,000.00 Price / Sales33.66 Cash FlowN/A Price / Cash FlowN/A Book Value$14.25 per share Price / Book0.16Miscellaneous Outstanding Shares1,610,000Free Float885,000Market Cap$3.70 million OptionableNo Data Beta0.46 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Matthew P. Blischak J.D.Chief Executive OfficerMr. Lance Thibault CPA (Age 58)Chief Financial Officer Mr. James S. Sigler MBA (Age 63)Executive Vice President of CMC Key CompetitorsTRACON PharmaceuticalsNASDAQ:TCONPalisade BioNASDAQ:PALIFresh Tracks TherapeuticsNASDAQ:FRTXKiromic BioPharmaNASDAQ:KRBP22nd Century GroupNASDAQ:XXIIView All CompetitorsInsidersJeffery A. SmisekSold 6,642 sharesTotal: $17,069.94 ($2.57/share)Jeffery A SmisekSold 1,470 sharesTotal: $5,350.80 ($3.64/share)View All Insider Transactions FNCH Stock Analysis - Frequently Asked Questions How have FNCH shares performed in 2024? Finch Therapeutics Group's stock was trading at $3.61 on January 1st, 2024. Since then, FNCH shares have decreased by 36.3% and is now trading at $2.30. View the best growth stocks for 2024 here. Are investors shorting Finch Therapeutics Group? Finch Therapeutics Group saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 9,200 shares, a decline of 20.7% from the March 15th total of 11,600 shares. Based on an average daily volume of 17,700 shares, the short-interest ratio is presently 0.5 days. Approximately 1.7% of the shares of the company are short sold. View Finch Therapeutics Group's Short Interest. When is Finch Therapeutics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our FNCH earnings forecast. How were Finch Therapeutics Group's earnings last quarter? Finch Therapeutics Group, Inc. (NASDAQ:FNCH) announced its quarterly earnings results on Monday, March, 25th. The company reported ($1.89) EPS for the quarter. When did Finch Therapeutics Group's stock split? Shares of Finch Therapeutics Group reverse split before market open on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Finch Therapeutics Group IPO? Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Finch Therapeutics Group? Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FNCH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
